UBS lowered the firm’s price target on Evolent Health (EVH) to $5 from $10 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $4 from $6 at Citi
- Evolent Health price target lowered to $6 from $10 at Truist
- Midday Fly By: Workday, Lowe’s in focus after earnings
- Balancing Near-Term Execution Risk With Long-Term EBITDA Upside: Why Evolent Remains a Buy Despite a Lowered Target
- Evolent Health price target lowered to $8 from $10 at BTIG